All In Biotech

Drug Trial Radar · NCT07364396

Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus

An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Feb 2026

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Lead sponsor
Curocell Inc.Industry
Sponsor type
Industry
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the safety and efficacy of CRC01, an investigational autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, in people with lupus nephritis (LN), a serious kidney complication of systemic lupus erythematosus (SLE). The main objectives of the study are: 1. To determine whether CRC01 infusion can improve kidney outcomes and reduce disease activity in participants with lupus nephritis. 2. To assess the safety profile, including potential risks such as cytokine release syndrome (CRS) and neurotoxicity. Study Design This is a single-arm, open-label, multi-center, Phase 1/2 study. All enrolled participants will receive CRC01 after screening and baseline assessments. Study Procedures Participants will: * Undergo eligibility screening, including blood tests, urine tests, and disease activity assessments. * Provide autologous T lymphocytes through a procedure called leukapheresis. * Receive a lymphodepleting pre-conditioning regimen (short course of chemotherapy). * Receive a single intravenous infusion of CRC01 cells. * Be hospitalized for close monitoring to detect and manage early adverse events such as CRS or neurotoxicity. * Return for scheduled follow-up assessments through Week 52 (12 months) post-infusion to evaluate safety and treatment response. Key Outcomes Researchers will measure: * Changes in proteinuria and kidney function. * Changes in disease activity scores. * Incidence and severity of adverse events.

Conditions

  • Lupus Nephritis
  • Lupus Nephritis (LN)
  • SLE
  • SLE (Systemic Lupus)

Interventions

  • CRC01Biological

    Autologous T lymphocytes genetically modified to express anti-CD19 chimeric antigen receptor (CAR). Administered as a single intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Study: To evaluate the tolerability of CRC01 in patients with severe refractory autoimmune disease (systemic lupus erythematosus), and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)Time frame: 28 day
  2. Phase 1 Study: To evaluate the tolerability of CRC01 in patients with severe refractory autoimmune disease (systemic lupus erythematosus), and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)Time frame: 28 day
  3. Phase 1 Study: To evaluate the tolerability of CRC01 in patients with severe refractory autoimmune disease (systemic lupus erythematosus), and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)Time frame: 28 day
  4. Phase 2 Study: To evaluate the efficacy of CRC01 by assessing Complete Renal Response (CRR)Time frame: 24 weeks
  5. Phase 2 Study: To evaluate the efficacy of CRC01 by assessing Complete Renal Response (CRR)Time frame: 24 weeks
  6. Phase 2 Study: To evaluate the efficacy of CRC01 by assessing Complete Renal Response (CRR)Time frame: 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.